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Abstract 
The P.N.E.I. (Psycho-Neuro-Endocrine-Immunology) approach is represented by the interdisciplinary concept of 
bidirectional cross-talk between the psycho-neuro-endocrine and immune systems, which can influence the 
immune response. The well-known Gut-Brain Axis and the Gut-Skin Axis can be merged in a bigger network- the 
Gut-Brain-Skin Axis, with complex regulation by cytokines, neuro-peptides, neuro-hormones and another 
messenger (signalling) molecules and maybe the most important modulator of the Gut-Brain-Skin Axis/ the gut 
microbiota. The role of gut bacterial homeostasis is very important, and the homeostatic imbalance of the immune 
response may be a relevant etiologic/pathophysiologic factor for extra-intestinal and intestinal inflammatory, 
allergic and autoimmune diseases. The Low Dose Cytokines Medicine (LDM) is an innovative therapeutic 
approach. It is based on the most advanced knowledge in molecular biology and low dose pharmacology with the 
primary outcome. The SKA (Sequential Kinetic Activation) technology, codified and standardised by GUNA S.p.a. 
-Italy- makes the low doses of signalling molecules able to be active even below the minimum dose classically 
considered as effective and the significative efficacy of orally administered low-dose signalling molecules is the 
most representative aspect of LDM. The Physiologic Nutraceuticals and the Low Dose Medicine are two of the 
most promising approaches for the treatment of skin diseases based on the rebalance of the immune response 
and the recovery of gut dysbiosis. 
 
 
 
 
 
 
 
Introduction 
 
The P.N.E.I. (Psycho-Neuro-Endocrine-
Immunology) approach is represented by the 
interdisciplinary concept of bidirectional cross-talk 
between the psycho-neuro-endocrine and immune 
systems, which can influence the immune response. 
Also, the immune system can influence the 
neuroendocrine functions, and this very complex 
interplay is mediated by a network of a lot of different 
hormones, neuropeptides, growth factors, cytokines 
and other signalling molecules [1], [2], [3]. 
Skin and gut roles and relations with other 
organs and tissues are examples of the P.N.E.I. 
functioning. They are complex immune and 
neuroendocrine organs integrated into the whole 
immune-endocrine systems and the most important 
contact organs of all animals with the environment, 
with a lot of common characteristics: colonized by 
specific microbial strains, with a large number of 
vascular and neural structures, constantly exposed to 
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a heavy antigenic charge, represented by bacterial 
flora, with the tolerance of the commensal microbiota. 
The well-known Gut-Brain Axis and the Gut-Skin Axis 
can be merged in a larger network-the Gut-Brain-Skin 
Axis, with complex regulation by cytokines, neuro-
peptides, neuro-hormones and other messenger 
(signaling) molecules and maybe the most important 
modulator of the Gut-Brain-Skin Axis/the gut 
microbiota [2], [3], [4], [5]. 
 
 
Gut microbiota 
 
It is well known that the gastrointestinal tract 
is colonised by about 100 trillion bacterial population 
(microbiota) composed of non-commensal 
(pathogenic) and commensal (nonpathogenic) 
species. Microbiota differs in composition and also in 
the function based on numerous factors such as the 
specific GI segment but also the diet of a subject, the 
gender, the age, etc. The nucleus of 57 species is 
common to all individuals, but each human being has 
a specific and unique microbiota. The dominant 
bacterial fila, constituting over 90% of the species 
present in the human intestine, are Bacteroides and 
Firmicutes, but also Lactobacilli, Bacteroides, 
Proteobacteria, Bifidobacteria and Streptococci are 
common [3], [4], [5], [6], [7]. 
The role of gut bacterial homeostasis is very 
important, and the homeostatic imbalance of the 
immune response may be a relevant etiologic factor 
for extra-intestinal and intestinal inflammatory, allergic 
and autoimmune diseases. This role is not limited to 
its systems but the whole organism [1], [4], [8]. 
Gram-negative bacteria, which contain 
lipopolysaccharide are considered as the main 
proinflammatory strains, responsible for the 
expression of pro-inflammatory cytokines such as 
Interleukin-1 (IL-1) and Interleukin-6 (IL-6) [2], [9]. 
Formation of biofilm is identified as one of the 
main forms of chronic intestinal, an adherent 
conglomerate to the intestinal epithelium having a 
composition like the extracellular matrix, in which 
bacteria and fungi proliferate and resid. The antibiotic 
treatment can affect mostly the bacterial infection 
caused by bacteria external to the biofilm, and an 
immune response is not able to be fully effective on 
biofilm. So, biofilm could be one of the most important 
etiological agents of numerous chronic inflammatory 
diseases, promote the persistence of a Low-Grade 
Chronic Inflammation (LGCI) that can lead to the 
Leaky Gut Syndrome, connected with the onset of 
autoimmune and allergic diseases [1], [10], [11], [12], 
[13]. 
The physiological inflammation is supported 
by Th1-related cytokines-IL-1, TNF-α and IL-6 and 
these cytokines induce the production of other pro-
inflammatory agents-adhesive molecules, 
chemokines, growth factors and other mediators such 
as prostaglandins and nitric oxide (NO) with the 
stimulation of the leukocyte at the site of inflammation. 
IL-6 acts as the secondary mediator, responsible for 
maintaining the inflammatory response itself. 
Inflammation leads to the increasing level of 
Interleukin-10 (IL-10), which is the most important Th2 
anti-inflammatory cytokine involved in the 
inflammation resolution phenomenon [3], [4], [12], 
[13], [14]. 
LGCI also has systemic effects, and it is often 
responsible for the disruption of skin immune 
homeostasis and systemic diseases such as obesity, 
Type II Diabetes, Vitiligo, Atopic Dermatitis, Psoriasis, 
BPCO (Bronco-Pulmonary-Chronic-Obstructive 
Pulmonary Disease) or the RRI (Recurrent 
Respiratory Infections), Rheumatoid Arthritis, etc. 
The key risk factor for the development of 
allergic sensitisation is the perturbation of microbiota 
development during the first years of life (due to 
maternal consumption of antimicrobials during 
pregnancy, formula feeding or antimicrobial exposure 
or caesarean birth) [15], [16], [17]. 
The presence of a shift (“Th1/Th2 shift”) of the 
immunological balance as a consequence of an 
imbalance between the cytokines expressed by 
Th1/Th17 and T-reg/Th2 lymphocyte subpopulations is 
one of the most important etiologic factors for a large 
number of dermatologic diseases. Th1 cytokines 
hyper-production is strictly linked with inflammatory 
and autoimmune skin diseases such as Psoriasis and 
Vitiligo, with the central role of a class of memory T-
cells characterised by the presence of the Cutaneous 
Lymphocyte Antigen (CLA) on their surface and 
responsible for skin-homing T cell. 
The presence of systemic LGCI is a strong 
trigger for CLA
+
 T-cells [17], [18], [19], [20]. 
As two of the most important etiologic factors 
for many of chronic dermatologic inflammatory, 
autoimmune and allergic diseases, gut dysbiosis 
(biofilm) and LGCI are currently considered 
therapeutic targets, but there are no standard 
therapeutic opportunities to treat LGCI. Also, and very 
important is that the chronic use of active anti-
inflammatory molecules designed for the treatment of 
acute inflammatory phenomena shows an 
unfavourable efficacy/adverse effects ratio. Anti-
cytokine therapy was proposed for the treatment of 
inflammatory and autoimmune diseases. The need of 
high doses of active molecules to reach the 
therapeutic goal and the low compliance of systemic 
administration performed by injective routes are the 
most important and limiting pitfalls connected with the 
use of high dosage cytokines and other signal 
molecules [21], [22], [23]. 
The Low Dose Cytokines Medicine (LDM) is 
an innovative therapeutic approach. It is based on the 
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most advanced knowledge in molecular biology and 
low dose pharmacology with the primary outcome. 
The SKA (Sequential Kinetic Activation) 
technology, codified and standardised by GUNA 
S.p.a. -Italy- makes the low doses of signalling 
molecules able to be active even below the minimum 
dose classically considered as effective and the 
significative efficacy of orally administered low-dose 
signalling molecules is the most representative aspect 
of LDM [17], [22], [23], [24]. 
The SKA of low dose signalling molecules 
activates some units of cellular (or plasmatic) 
receptors by their low concentration.  
The researchers performed a double-blind 
multicenter versus placebo clinical study was 
conducted on a dermatologic disease in 2014 for 
treating patients with Psoriasis Vulgaris in order to test 
the LDM approach with the oral administration of low 
dose SKA activated cytokines with the great 
effectiveness of the treatment assessing improvement 
of the psoriatic lesions and of quality of life (PASI 
(Psoriasis Area Severity Index) and ii) DLQI 
(Dermatology Life Quality Index). This study showed 
the effectiveness and the safety of the SKA low dose 
cytokines treatment and also that the SKA low dose 
cytokines treatment has a long action term, which 
extends over the months following the end of 
treatment [25], [26], [27], [28]. 
Lotti T. and colleagues, in 2015, were 
organised a retrospective clinical study and the 
effectiveness of adopted treatments for Vitiligo were 
compared and analysed the clinical data collected 
from patients who received different treatments for 
Vitiligo. Patients were treated with low-dose SKA IL-
10, IL-4; b-FGF and anti-IL-1antibodies, topical 
treatments with cortisone cream alone or in 
association with both groups of low dose molecules 
and nbUVB radiation alone or in association with both 
groups of molecules low dose. Other patients were 
treated with oral intake of extracts from Ginkgo biloba 
and with exposure to natural sunlight 
The treatment with low dose SKA b-FGF 
registered an improvement in 74% of the patients. The 
combination of low doses SKA IL-4, IL-10 and anti-IL-
1 antibodies registered an improvement in 77% of 
patients. The greatest improvement was registered 
with the association of treatments with low dose SKA 
molecules and UV-B treatment which has led to 
improvements in 92/93. No adverse effects have been 
reported, and the safety and efficacy of low dose SKA 
were verified [29], [30], [31]. The randomised, double-
blinded, controlled clinical trial included children with 
mild to medium IgE-mediated and non-IgE mediated 
Atopic Dermatitis in an acute phase of the disease 
was conducted using low dose SKA (IL-12 and IFN-γ). 
The main outcome was the reduction of the AD 
quantified as a reduction of SCORAD index of at least 
30%; in the same group, the decrease of SCORAD 
value continues during the follow-up period reaching 
64%. The treated group showed a significant 
reduction of the intake of drugs for symptoms control 
(antihistamines and topical corticosteroids) with 
progressive improvement of the quality of life. No 
adverse effects have been reported [32], [33], [34]. 
 
 
Conclusions 
 
The disruption of gut and skin homeostatic 
equilibrium has not only local but also systemic 
negative outcomes. Gut dysbiosis and inflammatory 
phenomena are one of the most important etiological 
components of many dermatologic diseases. 
A rebalance action of the gut microbiota and a 
rebalancing of the inflammatory immune response, for 
the treatment of many diseases, not adequately 
managed with currently available therapies, are 
needed.  
The study of biofilm formation and 
consolidation dynamics and the search for 
substances, of both natural and synthetic origin, able 
to intervene effectively on them, could be extremely 
useful. 
It is now possible to design an effective 
treatment protocol for dysbiosis using medical devices 
and food supplements, also useful to prevent both 
dysbiosis and biofilm formation. In selected cases, 
faecal transplantation is needed.  
The availability of Low Dose SKA signalling 
molecule is the most important point of LDM. Oral 
administration of low dose SKA signalling molecules 
represents the innovative core of the entire strategy 
for the treatment of dermatological diseases 
characterised by an immune imbalance and LGCI 
such as in Psoriasis Vulgaris, Vitiligo and Atopic 
Dermatitis. 
The Physiologic Nutraceuticals and the Low 
Dose Cytokines Medicine and faecal transplantation 
two of the most promising approaches for the 
treatment of skin diseases based on the rebalance of 
the immune response and the recovery of gut 
dysbiosis. 
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